Melinta Therapeutics, Inc.
Melinta Therapeutics is dedicated to providing innovative therapies for acute and life-threatening illnesses. The company focuses on serving patients with unmet needs through a diverse portfolio of antibiotics and other therapies. With a culture woven with tenacity, excellence, agility, integrity, and courage, Melinta aims to make a meaningful impact in the fight against antimicrobial resistance and improve patient care worldwide.
Industries
Nr. of Employees
medium (51-250)
Melinta Therapeutics, Inc.
Various locations including Parsippany, NJ and Lake Forest, IL
Patents
Products
Baxdela® (delafloxacin)
An antibiotic used for the treatment of bacterial infections.
Vabomere® (meropenem and vaborbactam)
A combination antibiotic for serious infections.
Orbactiv® (oritavancin)
A long-acting antibiotic for skin infections.
Minocin® (minocycline) for Injection
An antibiotic for various bacterial infections.
Kimyrsa™ (oritavancin)
A single-dose antibiotic for skin infections.
Baxdela® (delafloxacin)
An antibiotic used for the treatment of bacterial infections.
Vabomere® (meropenem and vaborbactam)
A combination antibiotic for serious infections.
Orbactiv® (oritavancin)
A long-acting antibiotic for skin infections.
Minocin® (minocycline) for Injection
An antibiotic for various bacterial infections.
Kimyrsa™ (oritavancin)
A single-dose antibiotic for skin infections.
News & Updates
Melinta's membership in the FIAC provides the opportunity for critical collaboration with the association and other organizations serving patients requiring infusion therapies.
Melinta announced ten scientific presentations with data on its portfolio of commercial and investigational stage products to be shared at IDWeek 2024.
Melinta's membership in the FIAC provides the opportunity for critical collaboration with the association and other organizations serving patients requiring infusion therapies.
Melinta announced ten scientific presentations with data on its portfolio of commercial and investigational stage products to be shared at IDWeek 2024.